Acuitive Technologies

Acuitive Technologies this week announced that it received FDA 510(k) clearance for its Citrespline and Citrelock ligament reconstruction devices.

The two systems are designed to firmly engage tendons and ligaments with a bone tunnel while preserving the integrity of the soft tissue during insertion of the device, according to the company. Citrespline and Citrelock are intended for use in orthopedic surgeries for the fixation of ligament or tendon tissue repairs of the knee, shoulder, elbow, wrist, hand, ankle and foot.

“This FDA clearance for the Citrespline and Citrelock system is a significant milestone that allows Acuitive to compete in the sports medicine market using innovative materials and designs that protect the soft tissue during insertion while improving fixation strength,” Acuitive Technologies managing partner Michael McCarthy said in a news release. “The Citrespline/Citrelock System is the third innovation from our robust pipeli…

Acuitive Technologies yesterday said it received FDA 510(k) clearance for its Citregen knotless suture anchor.

Citrefix is designed to assist in the attachment of tissue to the bone during orthopedic surgeries, such as fixation of ligaments or tendon graft tissue repairs of the shoulder, elbow, wrist, hand, knee, ankle and foot extremities.

“This FDA clearance for the Citrefix system is an important milestone for Acuitive,” managing partner Michael McCarthy said in a news release. “The Citrefix Knotless Suture Anchor System expands our reach in both the extremities and sports medicine Markets. It’s the second innovative product from our robust pipeline that is cleared for commercialization in the U.S.”

The Citrefix system features the company’s Citregen biomaterial that is designed on a molecular level to guide tissue regeneration by replicating the intrinsic cellular biochemical and structural support network. It rele…